secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001104659-26-025893
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics annual meeting elects three Class I directors, ratifies KPMG, approves say-on-pay
--------------------------------------------------------------------------------

- Yezan Haddadin, Faisal G. Sukhtian, Kurt J. Hilzinger elected as Class I directors with votes for >12M each.
- KPMG LLP ratified as independent auditor for FY2026 with 35.6M votes for, 0.8M against, 0.9M abstain.
- Non-binding advisory vote on exec compensation approved: 13.9M for, 1.5M against, 0.4M abstain.
- Approximately 50.7% of outstanding shares (37.3M of 73.5M) represented at meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926025893/0001104659-26-025893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926025893/tm268371d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-025893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer